<DOC>
	<DOCNO>NCT00158691</DOCNO>
	<brief_summary>Prospective randomize study order compare intravenous versus subcutaneous administration amifostine patient receive radiotherapy head neck cancer . Salivary flow evaluate year treatment clinical evaluation , measure weight saliva patient benefit questionnaire cotation .</brief_summary>
	<brief_title>Intravenous Versus Subcutaneous Amifostine Prevention Xerostomia After RT Head Neck Carcinomas</brief_title>
	<detailed_description>Prospective randomize study order compare intravenous ( IV ) versus subcutaneous ( SC ) administration amifostine patient receive radiotherapy head neck cancer . IV administration amifostine 200 mg/m2/day short 3-min infusion 15 30 min fraction radiotherapy . SC administration 500mg/day two slow 1.25 ml injection two different site 20 60 min radiotherapy fraction . Procedure require antiemetic treatment blood pressure monitoring arm .</detailed_description>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Amifostine</mesh_term>
	<criteria>newly diagnose squamous cell head neck cancer inclusion least 75 % parotid gland within radiation field would receive least 40 Gy Neutrophils ≥ 2000 / mm , Platelets ≥ 100,000 / mm3 , Creatinine &lt; 130 / mmol.L1 , Transaminase ≤ 3 x upper limit Distant metastases Prophylactic use pilocarpine Concomitant chemotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Head Neck cancer</keyword>
	<keyword>Radiotherapy</keyword>
	<keyword>Xerostomia</keyword>
	<keyword>Randomized trial</keyword>
</DOC>